Hematopoietic stem cells (HSCs) are unique cells that give rise to blood and immune system cells and have emerged as a crucial target in the treatment of various blood disorders. Hematopoietic stem cell gene therapy (HSC-GT), which utilizes genetic modification to treat these cells, is an innovative approach aimed at replacing damaged cells with healthy ones. This therapy is particularly used for treating inherited blood disorders, immune system disorders, and certain metabolic diseases. The treatment process involves modifying the patient’s own stem cells with genetic material in the laboratory and then reintroducing the corrected cells back into the patient.
In a study conducted by Calabria and colleagues, the long-term lineage connection in HSC-GT and the role of this method in treating various genetic disorders were examined. The research is based on long-term follow-up results from 53 patients. The study focused on individuals with diseases such as Metachromatic Leukodystrophy Syndrome (MLD), Wiskott-Aldrich Syndrome (WAS), and Beta Thalassemia (β-Thal), and evaluated the effects of these diseases on hematopoietic regeneration and clonal cell populations following treatment. The patients’ stem cells were genetically modified using lentiviral vectors, and their hematopoietic and immunological regeneration processes were monitored over an eight-year period.
The study results showed that each genetic disorder has its own unique hematopoietic regeneration process. For example, in MLD patients, myeloid-derived cells became more dominant in clonal populations, while in WAS patients, lymphoid populations, and in β-Thal patients, erythroid cell populations were more prominent. These observations reflect the varying levels of hematopoietic stress and genetic background effects on the stem cells’ proliferation and lineage connections for each disease.
The study emphasizes the ability of HSCs to adapt to the specific requirements of the disease. The findings demonstrate that HSC-GT offers an effective solution for the long-term treatment of genetic disorders, as the stem cells adjust to the hematopoietic regeneration process after genetic modification.
In conclusion, the study provides important findings supporting the safety and efficacy of HSC-GT as a long-term treatment for genetic diseases. The results, which show that HSCs restructure according to the disease’s needs and respond to disease-specific requirements, offer valuable insights into the safety of genetic therapies. Discovering the unique regeneration processes of each disease provides information that can help optimize genetic treatment approaches and pave the way for the development of new strategies for treating genetic disorders.
Author: Aleyna Balaban
Editor: Fatma Duran
Reference: Calabria A, Spinozzi G, Cesana D, Buscaroli E, Benedicenti F, Pais G, Gazzo F, Scala S, Lidonnici MR, Scaramuzza S, Albertini A, Esposito S, Tucci F, Canarutto D, Omrani M, De Mattia F, Dionisio F, Giannelli S, Marktel S, Fumagalli F, Calbi V, Cenciarelli S, Ferrua F, Gentner B, Caravagna G, Ciceri F, Naldini L, Ferrari G, Aiuti A, Montini E. Long-term lineage commitment in hematopoietic stem cell gene therapy. Nature. 2024 Oct 23. https://doi.org/10.1038/s41586-024-08250-x
-Bioinfocodes Scientific News Service-
News articles prepared by our team members, reviewing and compiling scientific research published in journals with an impact factor greater than 20 (click here for the list).